Form 4: Mineralys CMO Sells Shares After Option Exercise

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised stock options and subsequently sold common stock under a pre-arranged 10b5-1 trading plan.

Summary

• David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc. [MLYS], reported transactions involving company common stock.
• On January 13, 2026, Rodman exercised options to acquire 3,542 shares at $10.20 per share and 4,167 shares at $14.25 per share.
• On the same day, he sold 7,709 shares of common stock at $32.75 per share.
• On January 14, 2026, he sold an additional 11,367 shares at a weighted-average price of $32.6071, with prices ranging from $31.99 to $32.91.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• Following these transactions, Rodman directly beneficially owns 50,437 shares of common stock.
• He also holds derivative securities (stock options) for 131,042 shares (exercise price $10.20, expiring 02/13/2035) and 104,167 shares (exercise price $14.25, expiring 02/13/2034).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, reducing the implication of immediate negative sentiment. The significant gain from option exercise is a positive for the insider.

Positives

• The exercise of stock options indicates that the Chief Medical Officer realized value from previously granted equity incentives.
• The sale prices ($32.75 and $32.6071) are significantly higher than the exercise prices ($10.20 and $14.25), indicating a substantial gain for the reporting person.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests a pre-planned sale strategy rather than a reaction to immediate company news.

Negatives

• The sale of 19,076 shares by a Chief Medical Officer could be perceived by some investors as a lack of confidence, although mitigated by the 10b5-1 plan.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to Mineralys Therapeutics and its Chief Medical Officer. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing reports an individual insider transaction and does not provide data for comparison to global benchmarks, comparable companies, projects, or results.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal, though the 10b5-1 plan mitigates immediate concerns. The overall impact is likely minor given the pre-planned nature.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• This Form 4 filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Keywords

MLYS, Mineralys Therapeutics, Insider Trading, Form 4, Stock Options, Share Sale, Chief Medical Officer, 10b5-1 Plan